Ocugen (OCGN) Interest & Investment Income (2017 - 2026)
Ocugen's (OCGN) quarterly Interest & Investment Income came in at $100000.0 in Q1 2026, down 66.67% YoY from $300000.0 in Q1 2025, and down 65.87% on a QoQ basis from $293000.0 in Q4 2025.
Ocugen (OCGN) Interest & Investment Income (2017 - 2026) Analysis & Trends
Ocugen (OCGN) has 8 years of Interest & Investment Income data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 66.67% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $900000.0 (down 18.55% YoY) and the FY2025 annual result came in at $922000.0, down 29.08% from the prior year.
- Interest & Investment Income slipped to $100000.0 in Q1 2026, from $293000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $500000.0 in Q4 2024 to a low of $100000.0 in Q1 2026.
- A 3-year average of $283333.3 and a median of $296500.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income sank 31.0% — and 2026, when it slumped 66.67%.
- Tracing OCGN's Interest & Investment Income over 3 years: stood at $500000.0 in 2024, then sank by 41.4% to $293000.0 in 2025, then plunged by 65.87% to $100000.0 in 2026.
- The last three Interest & Investment Income figures came in at $100000.0 (Q1 2026), $293000.0 (Q4 2025), and $207000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 293,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Dec 31, 2020 | 1,065.00 |
| Mar 31, 2020 | 119.00 |
| Dec 31, 2019 | 107.00 |
| Sep 30, 2019 | 136.00 |
| Jun 30, 2019 | 377.00 |
| Mar 31, 2019 | 594.00 |
| Dec 31, 2018 | 1,820.00 |
| Sep 30, 2018 | 3,762.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 4,000.00 |
| Mar 31, 2017 | -6,000.00 |